Article Text

Download PDFPDF
Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer
  1. E. Stoeckle*,
  2. P. Paravis*,
  3. A. Floquet,
  4. L. Thomas,
  5. C. Tunon De Lara*,
  6. E. Bussières*,
  7. G. Macgrogan§,
  8. V. Picot and
  9. A. Avril*
  1. * Department of Surgery, Institut Bergonié, Regional Cancer Center, Bordeaux Cedex, France
  2. Department of Medical Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux Cedex, France
  3. Department of Radiation Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux Cedex, France
  4. § Department of Pathology, Institut Bergonié, Regional Cancer Center, Bordeaux Cedex, France
  5. Department of Biostatistics Unit, Institut Bergonié, Regional Cancer Center, Bordeaux Cedex, France
  1. Address correspondence and reprint requests to: Dr E. Stoeckle, Department of Surgery, Institut Bergonié, Regional Cancer Centre, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France. Email: stoeckle{at}bergonie.org

Abstract

The objective of the present study was to improve the definitions of optimal and suboptimal surgery in ovarian cancer. A retrospective prognostic factor analysis was done in a series of 433 patients with advanced ovarian cancer (stages III and IV) treated during the cisplatine era from 1980 to 1997 with assessment of postoperative residual disease by number and ranges of size of peritoneal nodules. Mean age of patients was 56.7 years. Median follow-up of patients alive was 138 months (range: 6–266 months). Median overall survival was 23 months. Significant prognostic factors for overall survival in univariate analysis were age, the presence of ascites, FIGO stage, treatment period, histological subtype, grade, results of surgery as defined by size and number of residual nodules. In multivariate analysis, quality of surgery defined by no versus few versus numerous residual nodules showed to remain an independent prognostic factor for outcome (P = 0.003), whereas size of residual nodules did not achieve significance. In conclusion, only complete surgery (no residual nodules) confers a real survival advantage. Cytoreduction to few and small nodules is associated with favorable outcome and could be qualified as optimal. Otherwise, cytoreduction leaving numerous nodules, whatever their size, remains suboptimal. Such patients should be considered for neo-adjuvant chemotherapy.

  • number
  • optimal surgery
  • ovarian cancer
  • residual nodules
  • size

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Paper given at the 13th International meeting of the European Society of Gynaecological Oncology (ESGO), Brussels, April 6–10, 2003.